Keywords:
ADDN; Glycaemic outcomes; Type 1 diabetes; glycated haemoglobin
Abstract:
The goal of therapy in Type 1 diabetes is to achieve optimal glycaemic targets and reduce complications. Robust data representing glycaemic outcomes across the lifespan are lacking in Australasia.